Pfizer Chairman and CEO Albert Bourla says the company is still in the market for acquisitions following its $43 billion acquisition of cancer biotech firm Seagen Inc., but 2024 will not see any major M&A activity from the company. He speaks with David Westin on "Wall Street Week Daily."
--------
Follow Bloomberg for business news & analysis, up-to-the-minute market data, features, profiles and more: [ Ссылка ]
Connect with us on...
Twitter: [ Ссылка ]
Facebook: [ Ссылка ]
Instagram: [ Ссылка ]
